Commentary on: Towards the use of non-psychoactive cannabinoids for prostate cancer

British Journal of Pharmacology

Volumn 168, Issue 1, 2013, Pages 76-78

  Pacher, Pál ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

cancer; cannabidiol; cannabinoid; Cannabis sativa; non psychoactive; phytocannabinoids; prostate

Indexed keywords

BICALUTAMIDE; CANNABIDIOL; CANNABINOID DERIVATIVE; CANNABIS; DOCETAXEL; DRONABINOL; NABILONE; NABIXIMOLS; TETRAHYDROCANNABINOLIC ACID; CANNABINOID; TRANSIENT RECEPTOR POTENTIAL CHANNEL; TRANSIENT RECEPTOR POTENTIAL CHANNEL M; TRPM8 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; APPETITE DISORDER; CANCER PAIN; DRUG EFFECT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MENTAL DISEASE; NAUSEA; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; ANIMAL; DRUG ANTAGONISM; MALE; NOTE; PATHOLOGY; PROSTATE TUMOR;

ANIMALS; CANNABIDIOL; CANNABINOIDS; HUMANS; MALE; PROSTATIC NEOPLASMS; TRANSIENT RECEPTOR POTENTIAL CHANNELS; TRPM CATION CHANNELS;

EID: 84872840715     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02121.x     Document Type: Review

References (15)

1. Alexander SPH, Mathie A, Peters JA, (2011). Guide to Receptors and Channels (GRAC), 5th edition (2011). Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. De Petrocellis L, Ligresti A, Schiano Moriello A, Iappelli M, Verde R, Stott CG, et al. (2012). Non-THC cannabinoids counteract prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms. Br J Pharmacol 168: 79-102.
3. Diaz-Laviada I, (2011). The endocannabinoid system in prostate cancer. Nat Rev Urol 8: 553-561.
4. Guindon J, Hohmann AG, (2011). The endocannabinoid system and cancer: therapeutic implication. Br J Pharmacol 163: 1447-1463.
5. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R, (2009). Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 30: 515-527.
6. Massi P, Solinas M, Cinquina V, Parolaro D, (2012). Cannabidiol as potential anticancer drug. Br J Clin Pharmacol doi: 10.1111/j.1365-2125.2012. 04298.x [Epub ahead of print].
7. Mukhopadhyay P, Rajesh M, Horvath B, Batkai S, Park O, Tanchian G, et al. (2011). Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. Free Radic Biol Med 50: 1368-1381.
8. Pacher P, Batkai S, Kunos G, (2006). The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 58: 389-462.
9. Pan H, Mukhopadhyay P, Rajesh M, Patel V, Mukhopadhyay B, Gao B, et al. (2009). Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death. J Pharmacol Exp Ther 328: 708-714.
10. Russo EB, (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol 163: 1344-1364.
11. Sarfaraz S, Afaq F, Adhami VM, Mukhtar H, (2005). Cannabinoid receptor as a novel target for the treatment of prostate cancer. Cancer Res 65: 1635-1641.
12. Sarfaraz S, Adhami VM, Syed DN, Afaq F, Mukhtar H, (2008). Cannabinoids for cancer treatment: progress and promise. Cancer Res 68: 339-342.
13. Schroder FH, (2010). Prostate cancer around the world. An overview. Urol Oncol 28: 663-667.
14. Solinas M, Massi P, Cantelmo A, Cattaneo M, Cammarota R, Bartolini D, et al. (2012). Cannabidiol inhibits angiogenesis by multiple mechanisms. Br J Pharmacol 167: 1218-1231.
15. Velasco G, Sanchez C, Guzman M, (2012). Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer 12: 436-444.